Search

• ViiV Healthcare to present first head-to-head data for long-acting HIV treatment Cabenuva against daily oral Biktarvy at CROI 2023

  Media

  Other key data to be presented include new HIV prevention findings for long-acting cabotegravir  and predictors of response to N6LS

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-to-present-first-head-to-head-data-for-long-acting-hiv-treatment-cabenuva-against-daily-oral-biktarvy-at-croi-2023/

  First published: 14 February 2023

• ViiV Healthcare to present new long-term findings from its innovative 2-drug and long-acting HIV medicines portfolio at CROI 2022

  Media

  ViiV Healthcare to present new long-term findings at CROI 2022

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-to-present-new-long-term-findings-from-its-innovative-2-drug-and-long-acting-hiv-medicines-portfolio-at-croi-2022/

  First published: 07 February 2022

• IDWeek 2019: ViiV Healthcare to present 20 abstracts from its innovative R&D portfolio with focus on 2-drug and long-acting regimens and mental health impact of HIV

  Media

  Presentations include six-year data for the investigational regimen of cabotegravir and rilpivirine.

  https://www.gsk.com/en-gb/media/press-releases/idweek-2019-viiv-healthcare-to-present-20-abstracts-from-its-innovative-rd-portfolio-with-focus-on-2-drug-and-long-acting-regimens-and-mental-health-impact-of-hiv/

  First published: 02 October 2019

• ViiV Healthcare to present new data from innovative HIV treatment and prevention portfolio at AIDS 2022

  Media

  Data to be presented include long-term and real-world data from portfolio of medicines

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-to-present-new-data-from-innovative-hiv-treatment-and-prevention-portfolio-at-aids-2022/

  First published: 25 July 2022

• IAS 2019: ViiV Healthcare showcasing innovation in HIV science

  Media

  challenging the current treatment paradigm and investigating new options to meet the evolving needs of people living with HIV

  https://www.gsk.com/en-gb/media/press-releases/ias-2019-viiv-healthcare-showcasing-innovation-in-hiv-science/

  First published: 15 July 2019

• ViiV Healthcare to present new data from diverse portfolio and pipeline of 2-drug and long-acting regimens for HIV treatment and prevention at IAS 2021

  Media

  Data to be presented underscore the commitment to developing innovative treatment and prevention options

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-to-present-new-data-from-diverse-portfolio-and-pipeline/

  First published: 17 July 2021

• EACS 2019: ViiV Healthcare to present 17 abstracts from its portfolio addressing the diverse needs of people living with HIV

  Media

  Data presentations expand understanding of ViiV Healthcare’s pipeline for heavily treatment-experienced populations.

  https://www.gsk.com/en-gb/media/press-releases/eacs-2019-viiv-healthcare-to-present-17-abstracts-from-its-portfolio-addressing-the-diverse-needs-of-people-living-with-hiv/

  First published: 06 November 2019

• GSK delivers sales and earnings growth in Q2 2019

  Media

  Total EPS 19.5p, +>100% AER, +>100% CER; Adjusted EPS 30.5p +9% AER, +4% CER

  https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-sales-and-earnings-growth-in-q2-2019/

  First published: 24 July 2019

• ViiV Healthcare presents GEMINI 1 & 2 studies through Week 96 showing 2-drug regimen of dolutegravir plus lamivudine continues to demonstrate high efficacy rates and no cases of treatment emergent resistance

  Media

  ViiV - GEMINI 1 & 2 studies through Week 96 showing 2-drug regimen of dolutegravir & lamivudine continues to demonstrate high efficacy rates

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-gemini-1-2-studies-through-week-96-showing-2-drug-regimen-of-dolutegravir-plus-lamivudine-continues-to-demonstrate-high-efficacy-rates/

  First published: 24 July 2019

• ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with a 2-drug regimen of dolutegravir plus lamivudine in virally suppressed patients switching from a TAF-containing, 3-drug regimen

  Media

  Week 48 results from the TANGO study will be presented this month at 10th International AIDS Society Conference on HIV Science (IAS 2019).

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-phase-iii-study-meets-primary-endpoint/

  First published: 10 July 2019